Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study - Wikidata - awgldk - TriplyDB

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study

http://www.wikidata.org/entity/Q33932391

about

Administration of Intravenous Inf liximab for Prevention of Peritoneal Adhesions Formation in Rats.Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland

P2860

Q36631083-50210AA9-241C-45D2-A6B9-21F8AD6601A6 Q58800873-E8E2243E-981C-473C-862D-CC9EF9B905AD

P2860

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study

http://www.wikidata.org/entity/Q33932391

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effectiveness of anti-tumor ne ...... arthritis: observational study

@ast

Effectiveness of anti-tumor ne ...... arthritis: observational study

@en

type

label

Effectiveness of anti-tumor ne ...... arthritis: observational study

@ast

Effectiveness of anti-tumor ne ...... arthritis: observational study

@en

prefLabel

Effectiveness of anti-tumor ne ...... arthritis: observational study

@ast

Effectiveness of anti-tumor ne ...... arthritis: observational study

@en

P1433

Q33932391-9C588D93-4BEE-4BAE-B7E1-8C37F62691B5

P1476

Q33932391-189DD3AD-360C-467A-9C21-1E02350FDF42

P2093

Q33932391-0EC83323-F953-4EF0-8D6F-E675D0C9CD80

Q33932391-2D237369-2021-408B-AAAC-BB4FEBAB2C05

Q33932391-3CEC4C65-825D-4999-970D-7AF846020F46

Q33932391-5A29A4FB-4F2C-4EBB-97BF-2AB539AAB53E

Q33932391-E739E540-696B-4538-BC7A-199E75036A9F

P2860

Q33932391-00B0A4E7-7833-46EB-9A0E-6D7078975BE9

Q33932391-16594ECC-4337-4C05-87F6-2B5EF54B5B8A

Q33932391-298CE82C-D84F-473C-A2A9-E3861228FDE2

Q33932391-2D82B017-AE68-485D-83A8-F58DCAEB4FF4

Q33932391-5F1B64AB-4E35-41B5-81BE-5D2CAEFB4F06

Q33932391-6BCBE958-B231-41A9-B2FB-238CE0A07C16

Q33932391-71211CFD-0E73-47C0-931C-3D8D3A1146E1

Q33932391-76353B23-4FC0-4C0B-9ADA-D6F452056996

Q33932391-7B29896C-3C4C-42C0-A1AA-FBC927F0A4CA

Q33932391-9264C4E1-85F0-4BCE-B47D-7470588ADA9B

P304

Q33932391-A7E1503C-1600-46C9-B0CE-176B0C06FCD1

P31

Q33932391-D48C8134-E5DD-4691-975D-31385E6792F3

P433

Q33932391-D3BFBB78-A959-4511-8CE8-A12F4FDE6407

P478

Q33932391-6EF74B82-4B3A-4CAA-959A-E78E63C9FAAD

P577

Q33932391-0CAE372E-F238-4183-8849-EA51463BD9DD

P698

Q33932391-E55D932B-8CEC-401B-B41D-DB7E9933E907

P932

Q33932391-EC5D52A2-7252-4885-82FE-AF9316D0325A

P1433

American health & drug benefits

P1476

Effectiveness of anti-tumor ne ...... arthritis: observational study

@en

P2093

Anna D'Souza

http://www.w3.org/2001/XMLSchema#string

Boxiong Tang

http://www.w3.org/2001/XMLSchema#string

Brian L Meissner

http://www.w3.org/2001/XMLSchema#string

Catherine T Piech

http://www.w3.org/2001/XMLSchema#string

R Scott McKenzie

http://www.w3.org/2001/XMLSchema#string

P2860

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Anti-TNFalpha therapy for rheumatoid arthritis: an update.

Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care.

Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.

Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?

P304

266-273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25126319

http://www.w3.org/2001/XMLSchema#string

P932

4106598

http://www.w3.org/2001/XMLSchema#string